Prospective, Multicenter, Epidemiological Study To Determine The Clinical, Molecular And Genetic Factors Associated To The Prognosis Of Patients With Advanced Renal Cell Carcinoma

Pfizer1 site in 1 country145 target enrollmentMay 2009

ConditionsCarcinoma, Renal Cell

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Carcinoma, Renal Cell
Sponsor: Pfizer
Enrollment: 145
Locations: 1
Primary Endpoint: Progression-free survival
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.

Detailed Description

invitation to volunteer

Registry

clinicaltrials.gov

Start Date

May 2009

End Date

September 2011

Last Updated

14 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Pfizer

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
•=18 years, any gender.
•Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion Criteria

•Patients who have already initiated any kind of specific therapy for the treatment of RCC.
•Patients with other neoplasias different from RCC (current or past).